Literature DB >> 4029219

Kinetics of ketamine and its metabolites in rabbits with normal and impaired renal function.

J L Pedraz, J M Lanao, A Dominguez-Gil.   

Abstract

The plasma levels of ketamine, an anaesthetic, and its metabolites were studied in 10 rabbits with normal renal function and in 9 rabbits with varying degrees of experimentally induced renal impairment. All the animals received a single bolus type i.v. dose of 10 mg/kg of the drug. The results obtained reveal an apparent inhibition of the biotransformation of ketamine in rabbits with renal impairment in which the drug is accumulated. The plasma half-life of ketamine ranged from 0.74 h in rabbits with normal renal function to 2.6 h in the animals with severe renal impairment. The plasma levels of norketamine (metabolite I) did not alter significantly in states of renal impairment. However, the kinetics of the other metabolite (II), dehydronorketamine, did change significantly in renal impairment, due to its high renal excretion capacity.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4029219     DOI: 10.1007/BF03189695

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  9 in total

1.  Pharmacokinetics of ketamine in man.

Authors:  J Wieber; R Gugler; J H Hengstmann; H J Dengler
Journal:  Anaesthesist       Date:  1975-06       Impact factor: 1.041

Review 2.  Biotransformation and disposition of ketamine.

Authors:  T Chang; A J Glazko
Journal:  Int Anesthesiol Clin       Date:  1974

3.  COMPT, a time-sharing program for nonlinear regression analysis of compartmental models of drug distribution.

Authors:  M Pfeffer
Journal:  J Pharmacokinet Biopharm       Date:  1973-04

4.  Quantitative determination of ketamine and its metabolites in man by gas-liquid chromatography.

Authors:  J L Pedraz; E L Mariño; A Dominguez-Gil
Journal:  Farmaco Prat       Date:  1983-05

Review 5.  Drug metabolites in renal failure: pharmacokinetic and clinical implications.

Authors:  R K Verbeeck; R A Branch; G R Wilkinson
Journal:  Clin Pharmacokinet       Date:  1981 Sep-Oct       Impact factor: 6.447

6.  Does ketamine metabolite II exist in vivo?

Authors:  P Stenberg; J Idvall
Journal:  Br J Anaesth       Date:  1981-07       Impact factor: 9.166

7.  Increased D-glucaric acid excretion in children with renal disease.

Authors:  I Németh; T Szeleczki
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1980

8.  Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans.

Authors:  J A Clements; W S Nimmo; I S Grant
Journal:  J Pharm Sci       Date:  1982-05       Impact factor: 3.534

9.  Pharmacokinetics of ketamine and two metabolites in the dog.

Authors:  J S Kaka; W L Hayton
Journal:  J Pharmacokinet Biopharm       Date:  1980-04
  9 in total
  4 in total

1.  Prior determination of baseline minimum alveolar concentration (MAC) of isoflurane does not influence the effect of ketamine on MAC in rabbits.

Authors:  Giacomo Gianotti; Alexander Valverde; Melissa Sinclair; Doris H Dyson; Thomas Gibson; Ron Johnson
Journal:  Can J Vet Res       Date:  2012-10       Impact factor: 1.310

2.  Effects of enzyme induction, renal and cardiac function on ketamine plasma kinetics in patients with ketamine long-term analgosedation.

Authors:  C Köppel; I Arndt; K Ibe
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Jul-Sep       Impact factor: 2.441

3.  Effect of rifampicin on S-ketamine and S-norketamine plasma concentrations in healthy volunteers after intravenous S-ketamine administration.

Authors:  Ingeborg Noppers; Erik Olofsen; Marieke Niesters; Leon Aarts; René Mooren; Albert Dahan; Evan Kharasch; Elise Sarton
Journal:  Anesthesiology       Date:  2011-06       Impact factor: 7.892

4.  Chronic ketamine impairs fear conditioning and produces long-lasting reductions in auditory evoked potentials.

Authors:  Laura C Amann; Tobias B Halene; Richard S Ehrlichman; Stephen N Luminais; Nan Ma; Ted Abel; Steven J Siegel
Journal:  Neurobiol Dis       Date:  2009-05-23       Impact factor: 5.996

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.